Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Total Current Liabilities
ÂĄ129m
CAGR 3-Years
55%
CAGR 5-Years
32%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Total Current Liabilities
ÂĄ10.2B
CAGR 3-Years
61%
CAGR 5-Years
28%
CAGR 10-Years
41%
PeptiDream Inc
TSE:4587
Total Current Liabilities
ÂĄ16.8B
CAGR 3-Years
81%
CAGR 5-Years
68%
CAGR 10-Years
67%
Takara Bio Inc
TSE:4974
Total Current Liabilities
ÂĄ6.7B
CAGR 3-Years
-28%
CAGR 5-Years
7%
CAGR 10-Years
1%
Pharma Foods International Co Ltd
TSE:2929
Total Current Liabilities
ÂĄ19.8B
CAGR 3-Years
3%
CAGR 5-Years
40%
CAGR 10-Years
57%
C
Cuorips Inc
TSE:4894
Total Current Liabilities
ÂĄ166m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Total Current Liabilities?
Total Current Liabilities
129m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Total Current Liabilities amounts to 129m JPY.

What is Perseus Proteomics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
32%

Over the last year, the Total Current Liabilities growth was 16%. The average annual Total Current Liabilities growth rates for Perseus Proteomics Inc have been 55% over the past three years , 32% over the past five years .

Back to Top